NCT00304096View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

April 30, 2008

Conditions
Breast Cancer
Interventions
BIOLOGICAL

synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine

Trial Locations (1)

22908

University of Virginia Cancer Center, Charlottesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Virginia

OTHER

NCT00304096 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter